Preliminary results of the Adaptive COVID-19 Treatment Trial (ACTT) investigating remdesivir for the treatment of COVID-19 in hospitalized adults with evidence of lower respiratory tract involvement has been published in the New England Journal of Medicine . Of the FHI Clinical study team members, Danielle Fisher, Clinical Research Project Manager, and Wendi McDonald, Associate Project Manager, are listed on the manuscript for her contributions to the study.
news & events
Check out what we’ve been up to and where can we connect!
April 16, 2020
Our president and CEO, Ted FitzGerald, talks with Outsourcing-Pharma about our partnership with IDRI on an immunotherapy clinical trial to combat COVID-19.
April 3, 2020
FHI Clinical Inc. announces today it has partnered with Infectious Disease Research Institute (IDRI), a Seattle-based not-for-profit organization, to provide full-service contract research organization (CRO) capabilities for an immunotherapy clinical trial to combat moderate to severe cases of COVID-19.
December 20, 2019
FHI Clinical is pleased to announce that Rob King has joined the company as Chief Operating Officer.
November 5, 2019
FHI Clinical is pleased to announce that Jeff Cazeault has joined the company as Vice President, Business Development.
April 9, 2019
FHI Clinical, Inc. announces its launch today as a full-service contract research organization (CRO) with the global expertise, responsive approaches and proven solutions to manage complex clinical research in resource-limited settings around the world.
Missed the webinar? View the recording to hear industry infectious disease experts discuss the importance of quality historical, testing and tracking data for timely, coordinated responses to outbreaks.
FHI Clinical representatives will be present at the 11th Annual SCOPE Summit in Orlando, FL, February 18-21, 2020. Set up a meeting to discuss FHI Clinical’s operational experience around the world.